A Phase 2 interventional study of Abelacimab and Rivaroxaban in Atrial Fibrillation (AF) and Stroke, sponsored by Anthos Therapeutics, Inc.. Active, not recruiting at 92 sites in 7 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.
Sponsored by Anthos Therapeutics, Inc. · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 161 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 71st largest by enrollment of the 679 interventional ones that give a count, is one of 58 that started in 2021, is one of 55 in phase 2, reaches primary completion later than 6 of the 219 other live ones, and was the 712th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →161 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
Oslo University Hospital · Sites in United States, Belgium, France and 7 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 58 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,287 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
Anthos Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Anthos Therapeutics, Inc. has 4 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
76 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 76 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a CHA2DS2-VASc of ≥4 OR a CHA2DS2-VASc of ≥3 with at least 1 of the following:
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment group 1: Abelacimab low dose subcutaneous (s.c.) monthly Extension Treatment Group: Abelacimab high dose subcutaneous (s.c.) monthly
Biological: Abelacimab
Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly Extension Treatment Group: Abelacimab high dose subcutaneous (s.c.) monthly
Biological: Abelacimab
Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily.
Drug: Rivaroxaban
Abelacimab provided as liquid in vial (150 mg/mL)
Also known as: MAA868
Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
Incidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding Events
The number of participants experiencing the first occurrence of the composite of ISTH-defined major bleeding or CRNM bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
Time frame: Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
Incidence Rate of the First Occurrence of ISTH-defined Major Bleeding Events
The number of participants experiencing the first occurrence of ISTH-defined major bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
Time frame: Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
Incidence Rate of the First Occurrence of ISTH-defined Major or CRNM or Minor Bleeding Events
The number of participants experiencing the first occurrence of the composite of ISTH-defined major or CRNM or minor bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
Time frame: Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
| Milestone | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban |
|---|---|---|---|
| Started | 427 | 430 | 430 |
| Entered open-label | 250 | 240 | 215 |
| Completed | 382 | 391 | 389 |
| Not completed | 45 | 39 | 41 |
| Withdrew: Withdrawal by subject | 14 | 3 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Death | 31 | 36 | 34 |
The number of participants experiencing the first occurrence of the composite of ISTH-defined major bleeding or CRNM bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
| participants with event/100 person-years | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban |
|---|---|---|---|
| Incidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding Events | 2.64 | 3.22 | 8.39 |
The number of participants experiencing the first occurrence of ISTH-defined major bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
| participants with event/100 person-years | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban |
|---|---|---|---|
| Incidence Rate of the First Occurrence of ISTH-defined Major Bleeding Events | 0.99 | 1.22 | 3.73 |
The number of participants experiencing the first occurrence of the composite of ISTH-defined major or CRNM or minor bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
| participants with event/100 person-years | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban |
|---|---|---|---|
| Incidence Rate of the First Occurrence of ISTH-defined Major or CRNM or Minor Bleeding Events | 7.05 | 10.43 | 15.30 |
Collected over Adverse events (AEs) that started during or after the start of the treatment or started prior to the start of the treatment and increased in severity after the start of the treatment through each participant's derived End of Study date for the randomized period (up to 33 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abelacimab 90 mg (MAA868) | 31/427 (7.3%) | 158/425 (37.2%) | 215/425 (50.6%) |
| Abelacimab 150 mg (MAA868) | 36/430 (8.4%) | 157/427 (36.8%) | 257/427 (60.2%) |
| Rivaroxaban | 34/430 (7.9%) | 167/428 (39%) | 227/428 (53%) |
| Event | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban |
|---|---|---|---|
| Cardiac failureCardiac disorders | 26/425 | 20/427 | 18/428 |
| Atrial fibrillationCardiac disorders | 18/425 | 14/427 | 10/428 |
| PneumoniaInfections and infestations | 10/425 | 10/427 | 13/428 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/425 | 3/427 | 12/428 |
| AnaemiaBlood and lymphatic system disorders | 1/425 | 3/427 | 11/428 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 10/425 | 2/427 | 6/428 |
| COVID-19 pneumoniaInfections and infestations | 9/425 | 1/427 | 3/428 |
| DeathGeneral disorders | 9/425 | 4/427 | 6/428 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 7/425 | 3/427 | 5/428 |
| Urinary tract infectionInfections and infestations | 4/425 | 7/427 | 1/428 |
| Event | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban |
|---|---|---|---|
| COVID-19Infections and infestations | 41/425 | 48/427 | 45/428 |
| Atrial fibrillationCardiac disorders | 28/425 | 27/427 | 24/428 |
| Urinary tract infectionInfections and infestations | 27/425 | 24/427 | 12/428 |
| ContusionInjury, poisoning and procedural complications | 10/425 | 27/427 | 15/428 |
| HeadacheNervous system disorders | 13/425 | 27/427 | 11/428 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 23/425 | 26/427 | 27/428 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 11/425 | 9/427 | 27/428 |
| HypertensionVascular disorders | 24/425 | 26/427 | 20/428 |
| Back painMusculoskeletal and connective tissue disorders | 20/425 | 26/427 | 22/428 |
| AnaemiaBlood and lymphatic system disorders | 18/425 | 17/427 | 24/428 |
| Age, Customized(Participants) | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban | Total |
|---|---|---|---|---|
| ≥ 80 years | 87 | 81 | 90 | 258 |
| Sex/Gender, Customized(Participants) | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban | Total |
|---|---|---|---|---|
| Female sex | 195 | 193 | 184 | 572 |
| Race/Ethnicity, Customized(Participants) | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban | Total |
|---|---|---|---|---|
| White | 404 | 410 | 404 | 1218 |
| Asian | 20 | 15 | 24 | 59 |
| Black | 3 | 5 | 2 | 10 |
| Median Age(years) | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban | Total |
|---|---|---|---|---|
| Median | 75 (69 to 79) | 74 (69 to 78) | 74 (69 to 79) | 74 (69 to 78) |
| Region of Enrollment(Participants) | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban | Total |
|---|---|---|---|---|
| North America | 126 | 106 | 103 | 335 |
| Europe | 282 | 309 | 305 | 896 |
| Asia | 19 | 15 | 22 | 56 |
| Median body-mass index (IQR)(kg/m²) | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban | Total |
|---|---|---|---|---|
| Median | 29.5 (26.0 to 33.6) | 30.0 (26.7 to 34.5) | 30.3 (27.0 to 34.4) | 29.9 (26.6 to 34.2) |
| Creatinine clearance ≤50 ml/min(Participants) | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban | Total |
|---|---|---|---|---|
| Count of participants | 86 | 90 | 88 | 264 |
| Pattern of atrial fibrillation(Participants) | Abelacimab 90 mg (MAA868) | Abelacimab 150 mg (MAA868) | Rivaroxaban | Total |
|---|---|---|---|---|
| First detected or paroxysmal | 224 | 220 | 225 | 669 |
| Persistent or long-standing persistent | 87 | 84 | 97 | 268 |
| Permanent | 115 | 120 | 106 | 341 |
13 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2021 to primary completion in Feb 2024, 36 months.
Results were first posted in Jul 2025, 1 year 5 months after primary completion. A results delay was requested in Feb 2025.
Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 36 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abelacimab
Anthos Therapeutics, Inc.